Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NASDAQ | Common Stock
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally.
The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement.
The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders.
It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting.
The company was founded in 2011 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.07 Increased by +126.92% | -0.07 Increased by +200.00% |
| Mar 12, 24 | 0.07 Increased by +216.67% | 0.02 Increased by +250.00% |
| Nov 7, 23 | 0.05 Decreased by -37.50% | -0.02 Increased by +350.00% |
| Aug 8, 23 | 0.14 Increased by +40.00% | 0.03 Increased by +366.67% |
| May 16, 23 | -0.26 Decreased by -750.00% | -0.15 Decreased by -73.33% |
| Mar 31, 23 | -0.06 Decreased by -123.08% | 0.05 Decreased by -220.00% |
| Nov 8, 22 | 0.08 Decreased by -68.00% | 0.12 Decreased by -33.33% |
| Aug 11, 22 | 0.10 Decreased by -37.50% | 0.16 Decreased by -37.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 120.79 M Decreased by -11.87% | -7.30 M Decreased by -330.02% | Decreased by -6.05% Decreased by -361.01% |
| Jun 30, 23 | 137.07 M Decreased by -2.32% | -3.68 M Increased by +54.07% | Decreased by -2.69% Increased by +52.97% |
| Mar 31, 23 | 119.06 M Increased by +1.51% | -100.02 M Decreased by -575.52% | Decreased by -84.01% Decreased by -565.49% |
| Dec 31, 22 | 125.83 M Decreased by -3.51% | -44.87 M Decreased by -12.23 K% | Decreased by -35.66% Decreased by -12.68 K% |
| Sep 30, 22 | 137.07 M Increased by +25.88% | 3.17 M Increased by +396.45% | Increased by +2.32% Increased by +335.50% |
| Jun 30, 22 | 140.33 M Increased by +27.79% | -8.01 M Decreased by -94.23% | Decreased by -5.71% Decreased by -52.00% |
| Mar 31, 22 | 117.29 M Increased by +43.42% | -14.81 M Decreased by -159.38% | Decreased by -12.62% Decreased by -141.40% |
| Dec 31, 21 | 130.41 M Increased by +32.28% | -364.00 K Decreased by -113.11% | Decreased by -0.28% Decreased by -109.91% |